These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 2512048)

  • 1. In vitro comparison of cefpirome and four other beta-lactam antibiotics alone and in combination with tobramycin against clinical isolates of Pseudomonas aeruginosa.
    Cabezudo I; Pfaller M; Bale M; Wenzel R
    Diagn Microbiol Infect Dis; 1989; 12(4):337-41. PubMed ID: 2512048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergy of new C-3 substituted cephalosporins and tobramycin against Pseudomonas aeruginosa and Pseudomonas cepacia.
    Chin NX; Neu HC
    Diagn Microbiol Infect Dis; 1989; 12(4):343-9. PubMed ID: 2512049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Evaluation of bactericidal activity of cefpirome-aminoglycoside combination against Pseudomonas aeruginosa strains with intermediate sensitivity to cefpirome and in various phenotypes of beta-lactam resistance].
    Canis F; Cavallo JD; Husson MO
    Pathol Biol (Paris); 1997 May; 45(5):420-3. PubMed ID: 9296096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In-vitro activity of cefpirome compared with that of other agents.
    Raizes EG; Cantey JR
    J Antimicrob Chemother; 1988 Feb; 21(2):177-81. PubMed ID: 3129388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative antimicrobial activity of FK037, cefpirome, ceftazidime and cefepime against aminoglycoside-sensitive and aminoglycoside-resistant Pseudomonas aeruginosa and Pseudomonas spp.
    Baltch AL; Smith RP; Ritz W
    Chemotherapy; 1994; 40(6):391-8. PubMed ID: 7842822
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Goodlet KJ; Nicolau DP; Nailor MD
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of rifampicin on the in-vitro activity of cefpirome or ceftazidime in combination with aminoglycosides against Pseudomonas aeruginosa.
    Valdes JM; Baltch AL; Smith RP; Hammer MC; Ritz WJ
    J Antimicrob Chemother; 1990 Apr; 25(4):575-84. PubMed ID: 2112539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Antimicrobial susceptibility of Pseudomonas aeruginosa isolated in Fukushima Prefecture].
    Niitsuma K; Saitoh M; Kojimabara M; Kashiwabara N; Aoki T; Tomizawa M; Maeda J; Kosenda T
    Jpn J Antibiot; 2001 Feb; 54(2):79-87. PubMed ID: 11338681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of cefpirome (HR810) against Pseudomonas aeruginosa strains with characterised resistance mechanisms to beta-lactam antibiotics.
    Gargalianos P; Oppenheim BA; Skepastianos P; Livermore DM; Williams RJ
    J Antimicrob Chemother; 1988 Dec; 22(6):841-8. PubMed ID: 3149631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of chronic pseudomonas aeruginosa infection in cystic fibrosis patients with ceftazidime and tobramycin.
    Heilesen AM; Permin H; Koch C; Høiby N
    Scand J Infect Dis; 1983; 15(3):271-6. PubMed ID: 6417770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro susceptibility of Streptococcus pneumoniae strains to nine beta-lactam antibiotics and the killing kinetics of cephalosporins alone and in combination with vancomycin or gentamicin.
    Marton A; Major P
    Microb Drug Resist; 1996; 2(3):361-9. PubMed ID: 9158796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergism between tobramycin and ceftazidime against a resistant Pseudomonas aeruginosa strain, tested in an in vitro pharmacokinetic model.
    den Hollander JG; Horrevorts AM; van Goor ML; Verbrugh HA; Mouton JW
    Antimicrob Agents Chemother; 1997 Jan; 41(1):95-100. PubMed ID: 8980762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Susceptibility of 100 blood isolates of Pseudomonas aeruginosa to 19 antipseudomonal antibiotics: old and new.
    Korvick J; Yu VL; Hilf M
    Diagn Microbiol Infect Dis; 1987 Jun; 7(2):107-11. PubMed ID: 3115670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicentre comparative study on the antibacterial activity of FK-037, a new parenteral cephalosporin.
    Martínez-Beltrán J; Cantón R; Liñares J; García de Lomas J; Gimeno C; Tubau F; Baquero F
    Eur J Clin Microbiol Infect Dis; 1995 Mar; 14(3):244-52. PubMed ID: 7614970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative synergistic activity of cefoperazone, cefotaxime, moxalactam, and carbenicillin, combined with tobramycin, against Pseudomonas aeruginosa.
    Mintz L; Drew WL
    Antimicrob Agents Chemother; 1981 Feb; 19(2):332-4. PubMed ID: 6289731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cross-susceptibility of cefpirome and four other beta-lactams against isolates from haematology/oncology and intensive care units. International Study Group.
    Spencer RC
    Scand J Infect Dis Suppl; 1993; 91():25-32. PubMed ID: 8290900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of antibacterial activities of meropenem and six other antimicrobials against Pseudomonas aeruginosa isolates from North American studies and clinical trials.
    Iaconis JP; Pitkin DH; Sheikh W; Nadler HL
    Clin Infect Dis; 1997 Feb; 24 Suppl 2():S191-6. PubMed ID: 9126693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of cefotaxime-aminoglycoside combinations against aminoglycoside-resistant Pseudomonas.
    Murray PR
    Antimicrob Agents Chemother; 1980 Mar; 17(3):474-6. PubMed ID: 6252830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Activities of antipseudomonal agents against clinical isolates of Pseudomonas aeruginosa].
    Murase M; Miyamoto H; Handa T; Saheki S; Takeuchi N
    Jpn J Antibiot; 1995 Oct; 48(10):1581-9. PubMed ID: 8544340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [In vitro interaction of piperacillin and imipenem/cilastatin combined with aminoglycosides against Pseudomonas aeruginosa].
    Yamashiro Y; Ogake N; Takahata M; Minami S
    Jpn J Antibiot; 2000 Apr; 53(4):194-200. PubMed ID: 10868299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.